THE ROLE OF SOCIO-DEMOGRAPHIC FACTORS IN HPV INFECTION

Aim. Infections caused by highly oncogenic HPV types can persist in the human body, which increases the risk of developing severe cervical lesions with their subsequent progression to invasive cervical cancer. The aim of this study was to investigate the socio-demographic characteristics of patients with precancerous diseases of the cervix and analyze the relationship between HPV infections and cervical precancerous diseases.

Materials and methods. Data on the cervix and HPV infections were collected from 402 women included in the scientific project «National Program for the Study of HPV with the Development of an Integrated Approach to Effective Diagnosis and Treatment of Precancerous Conditions» between 2024 and 2026. The study is being conducted within the framework of program-targeted funding from the Ministry of Science and Education of the Republic of Kazakhstan.

Results and discussion. The average age of women in our study with a positive HPV test result was 33.08±6.62 years. Among women infected with HPV, every third woman was not married – 31.2%, the divorce rate is 12.8%. The barrier method of contraception is used in 33.8% of sample population. Furthermore, among HPV-infected women the usage of barrier contraception is 1.2 times higher. HPV-16 and HPV-52 were the most common types in patients with both normal and abnormal cytology. Mild and severe dysplasia were more frequently observed in HPV types 16, 33, 52, and 58.

Conclusion. Socio-demographic factors such as age and marital status have a significant impact on the risk of HPV infection. Young women and unmarried women, women with full-day work hours have a higher level of infection.

1. Aimagambetova G., Babi A., Issa T., Issanov A. What Factors Are Associated with Attitudes towards HPV Vaccination among Kazakhstani Women? Exploratory Analysis of Cross-Sectional Survey Data. Vaccines. 2022; 10 (5): 824. https://doi:10.3390/vaccines10050824

2. McBride A. A. Human malignancies associated with persistent HPV infection. The Oncologist. 2024; 29 (6): 457-464. https://doi:10.1093/oncolo/oyae071

3. Asthana S., Busa V., Labani S. Oral contraceptives use and risk of cervical cancer: a systematic review & meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 247: 163-175. https://doi:10.1016/j.ejogrb.2020.02.014

4. Sehnal B., Halaška M. J., Vlk R., Drochýtek V., Pichlík T., Hruda M., Robová H., Rob L., Tachezy R. Human papillomavirus infection (HPV) and pregnancy. Epidemiol. Mikrobiol. Imunol. 2024; 73 (1): 37-50. https://doi:10.61568/emi/11-6254/20240123/136241

5. Bao Y. P., Li N., Smith J. S., Qiao Y. L. ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int. J. Gynecol. Cancer. 2008; 18 (1): 71-79. https://doi:10.1111/j.1525-1438.2007.00959.x

6. Gonzalez-Yebra B., Mojica-Larrea M., Alonso R., Gonzalez A. L., Romero-Morelos P., Taniguchi-Ponciano K., Ruiz-Romero J. A., López-Romero R., Salcedo M. HPV infection profile in cervical lesions. Gac. Med. Mex. 2022; 158 (4): 222-228. https://doi:10.24875/GMM.M22000679

7. Canfell K., Smith M., Saville M., Arbyn M. HPV screening for cervical cancer is reaching maturity. BMJ. 2022; 377: 1303.

8. Celewicz A., Celewicz M., Michalczyk M., Rzepka R. Perspectives in HPV secondary screening and personalized therapy based on our understanding of HPV-related carcinogenesis pathways. Mediators Inflamm. 2020; 2020: 2607594. https://doi:10.1155/2020/2607594

9. de Sanjosé S., Brotons M., Pavón M. The natural history of human papillomavirus infection. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 47: 2-13.

10. Huang R., Liu Z., Sun T., Zhu L. Cervicovaginal microbiome, high-risk HPV infection and cervical cancer: mechanisms and therapeutic potential. Microbiol. Res. 2024; 287: 127857. https://doi:10.1016/j.micres.2024.127857

11. Yang H., Xie Y., Guan R., Zhao Y., Lv W., Liu Y., Zhu F., Liu H., Guo X., Tang Z., Li H., Zhong Y., Zhang B., Yu H. Factors affecting HPV infection in US and Beijing females: a modeling study. Front. Public Health. 2022; 10: 1052210. https://doi:10.3389/fpubh.2022.1052210

12. Ntanasis-Stathopoulos, I., Kyriazoglou, A., Liontos, M., Dimopoulos, M. A., Gavriatopoulou, M. Current trends in the management and prevention of human papillomavirus (HPV) infection. J. BUON. 2020; 25 (3): 1281-1285.

13. Kiseki H., Tsukahara Y., Tajima N., Tanaka A., Horimoto A., Hashimura N. Influence of co-infection complicated with human papillomavirus on cervical intraepithelial neoplasia development in patients with atypical squamous cells of undetermined significance. J. Infect. Chemother. 2017; 23 (12): 814-819. https:// doi:10.1016/j.jiac.2017.08.008

14. Lugović-Mihić L., Cvitanović H., Djaković I., Kuna M., Sesherko A. The influence of psychological stress on HPV infection manifestations and carcinogenesis. Cell Physiol. Biochem. 2021; 55 (2): 71-88. https://doi:10.33594/000000395

15. Luo Q., Zhang H., Zeng X., Han N., Ma Z., Luo H. HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study. BMC Infect. Dis. 2024; 24 (1): 804. https://doi:10.1186/s12879-024-09693-3

16. del Pino M., Vorsters A., Joura E. A., Doorbar J., Haniszewski M., Asensio Gudina I., Kodjamanova P., Velicer C., Drury R. Risk factors for human papillomavirus infection and disease: a targeted literature summary. J. Med. Virol. 2024; 96 (2): e29420. https://doi:10.1002/jmv.29420

17. Mortaki D., Gkegkes I. D., Psomiadou V., Blontzos N., Prodromidou A., Lefkopoulos, F., Nicolaidou E. Vaginal microbiota and human papillomavirus: a systematic review. J. Turk. Gynecol. Assoc. 2020; 21: 193-200. https://doi:10.4274/jtgga.galenos.2019.2019.0051

18. Okunade K. S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol. 2020; 40 (5): 602-608. https:// doi:10.1080/01443615.2019.1634030

19. Ren X., Hao Y., Wu B. Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: a meta-analysis. Front. Microbiol. 2022; 13: 1052324. https://doi:10.3389/fmicb.2022.1052324

20. Carse S., Bergant M., Schaefer G. Advances in targeting HPV infection as potential alternative preventive means. Int. J. Mol. Sci. 2021; 22 (4): 2201. https://doi:10.3390/ijms22042201

21. Teng P., Hao M. A population-based study of age-related associations between vaginal pH and the development of cervical intraepithelial neoplasia. Cancer Med. 2020; 9: 1890-1902.

22. Protasova A. E., Lyashchenko V. A. Socio-demographic and clinical-morphological features of common forms of invasive cervical cancer. Tumors Female Reprod. Syst. 2021; 17 (2): 93-99. https://doi:10.17650/1994-4098-2021-17-2-93-99

23. Eun T. J., Perkins R. B. Screening for cervical cancer. Med. Clin. North Am. 2020; 104 (6): 1063-1078. https://doi:10.1016/j.mcna.2020.08.006

24. Usyk M., Zolnik C. P., Castle P. E., Porras C., Herrero R., Gradissimo A., Gonzalez P., Safaeian M., Schiffman M., Burk R. D. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020; 16: e1008376. https://doi:10.1371/journal.ppat.1008376

25. Tamarelle J., Thiébaut A., de Barbeyrac B., Bébéar C., Ravel J., Delarocque-Astagneau E. The vaginal microbiota and its association with HPV, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin. Microbiol. Infect. 2018; 25: 35-47. https://doi:10.1016/j.cmi.2018.04.019

26. Tao X., Austin R. M., Yu T. Risk stratification for cervical neoplasia using extended high-risk HPV genotyping in women with ASC-US cytology: A large retrospective study from China. Cancer Cytopathol. 2022; 130 (4): 248-258. https://doi:10.1002/cncy.22536